title: Response to Smith and Brogly et al. commentaries on Zedler et al.
authors.affiliation: Venebio Group, LLC, Richmond, VA, USA.
authors.forename: Andrew R
authors.initials: AR
authors.lastname: Joyce
authors.affiliation: Venebio Group, LLC, Richmond, VA, USA.
authors.forename: Barbara K
authors.initials: BK
authors.lastname: Zedler
authors.affiliation: Venebio Group, LLC, Richmond, VA, USA.
authors.forename: Halle R
authors.initials: HR
authors.lastname: Amick
authors.affiliation: Venebio Group, LLC, Richmond, VA, USA.
authors.forename: E Lenn
authors.initials: EL
authors.lastname: Murrelle
authors.affiliation: UNC Horizons, Department of Obstetrics and Gynecology, School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.|Departments of Psychiatry and Behavioral Sciences and Obstetrics and Gynecology, School of Medicine, Johns Hopkins University, Baltimore, MD, USA.
authors.forename: Hendree E
authors.initials: HE
authors.lastname: Jones
mesh_terms: D002047:Buprenorphine; D005260:Female; D006801:Humans; D008691:Methadone; D058850:Opiate Substitution Treatment; D009293:Opioid-Related Disorders / Q000188:drug therapy*; D011247:Pregnancy; D011248:Pregnancy Complications / Q000188:drug therapy*
chemical_list: D002047:Buprenorphine; D008691:Methadone
keywords: Buprenorphine; meta-analysis; methadone; opioid use disorder; pregnancy; systematic review